Trial Profile
A Swedish National Register-Based Assessment for the factors associated with the use of Remicade and biosimilars
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jan 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatic disorders
- Focus Therapeutic Use
- 25 Jan 2017 New trial record